Compare Boeing Co (BA) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boeing Co vs Sana Biotechnology Inc — how do they compare? Boeing Co trades at $230.13 (market cap $184.35B), while Sana Biotechnology Inc trades at $3.81 (market cap $1.13B). The key difference: Boeing Co is far larger — about 163.1× Sana Biotechnology Inc's market cap, and Boeing Co pays a 0.03% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| BA | SANA | |
|---|---|---|
Market Cap | $184.35B | $1.13B |
Volume | 7,591,579 | — |
Sector | Industrials | Health |
52-Week High | $252.15 | $5.92 |
52-Week Low | $179.12 | $2.68 |
Enterprise Value | $210.23B | $1.05B |
Dividend Yield | 0.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boeing (BA) trades at $230.11, down 1.15% on the day, with a bullish technical signal and strong analyst support. The company shows improving fundamentals with 2025 revenue of $89.46 billion and net income of $2.24 billion, marking a return to profitability after three years of losses. Recent news highlights Boeing's strategic divestiture of non-core aviation technology units to Archer Aviation, allowing greater focus on core aerospace operations.
The outlook remains positive with 67% analyst buy ratings and a $280.83 consensus price target representing 22% upside potential. Key risks include execution challenges in production ramp-up, high debt levels, and competitive pressures. Earnings momentum is mixed with a recent Q2 2026 miss but beats in prior quarters, requiring monitoring of Q3 2026 results due soon.
SANA Biotechnology trades at $3.775, up 4.57% with strong technical momentum as moving averages signal bullish sentiment. The company shows significant financial challenges with negative ROE (-152.87%) and net income (-$244.17M in 2025), though recent analyst upgrades and clinical developments in cell therapy research provide optimism. Cash flow remains negative but improved from -$55M to -$14M year-over-year, while the stock benefits from 82% buy ratings from analysts.
Investment outlook balances high-risk fundamentals against promising biotechnology breakthroughs. The primary opportunity lies in successful clinical trial outcomes and market adoption of engineered cell therapies, while risks include sustained cash burn, execution challenges, and competitive pressures in the genomics space. Wall Street's $9.50 price target suggests substantial upside potential if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boeing Co
The Boeing Company, together with its subsidiaries, develops, produces, and markets commercial jet aircraft, as well as provides related support services to the commercial airline industry worldwide. The Company also researches, develops, produces, modifies, and supports information, space, and defense systems, including military aircraft, helicopters and space and missile systems.
Read more on BA →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
